Clinical Guidelines

GSK’s RSV Vaccine Moves Closer to China Approval 

Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year

  • By

  • February 18, 2026

  • 2 min

Share

  • 1

    Arexvy vaccine is for RSV prevention in adults 60+.

  • 2

    Over 350,000 hospitalizations for RSV annually in China.

  • 3

    Positive phase 3 trial results support regulatory submission.

  • 4

    First RSV vaccine in China for this demographic if approved.

  • 5

    Vaccination necessary due to aging population's increased risk.

Original Source(s)

GSK’s RSV Vaccine Moves Closer to China Approval 

Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year

  • February 18, 2026

  • 2 min

Related Content

Bacterial Pseudaminic Acid Emerges as an Immune Target

Glycoproteomic mapping reveals pseudaminic acid as a shared feature across pathogenic bacteria 

  • February 18, 2026

  • 2 min
Hot Springs Yield Robust Enzymes for Molecular Diagnostics

Phage enzymes from extreme environments studied for diagnostic use

  • February 18, 2026

  • 2 min
Conjugative CRISPR System Cuts Resistance

Mobile gene drive-like platform spreads between bacteria and reduces ampicillin resistance by up to 5 logs while enabling cassette reversal